Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immunotherapy—another breakthrough in gastrointestinal malignancies

Immunotherapy—another breakthrough in gastrointestinal malignancies Summary Immunotherapy is a breakthrough in different tumor entities. Recently, immunotherapy became an important treatment modality in gastrointestinal (GI) malignancies. In GI malignancies, immunotherapy with or without chemotherapy or targeted agents is revolutionizing the treatment landscape and our daily clinical practice. In this review, we discuss the relevance of immunotherapy in GI malignancies and provide a perspective on promising upcoming treatment strategies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Immunotherapy—another breakthrough in gastrointestinal malignancies

Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/immunotherapy-another-breakthrough-in-gastrointestinal-malignancies-9QNkxxHC87
Publisher
Springer Journals
Copyright
2022 The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-021-00785-3
Publisher site
See Article on Publisher Site

Abstract

Summary Immunotherapy is a breakthrough in different tumor entities. Recently, immunotherapy became an important treatment modality in gastrointestinal (GI) malignancies. In GI malignancies, immunotherapy with or without chemotherapy or targeted agents is revolutionizing the treatment landscape and our daily clinical practice. In this review, we discuss the relevance of immunotherapy in GI malignancies and provide a perspective on promising upcoming treatment strategies.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Feb 1, 2022

Keywords: oncology; medicine/public health, general

References

  • Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)
    EJ Ruiter, FJ Mulder, BM Koomen
  • Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
    DT Le, JN Durham, KN Smith
  • Pembrolizumab plus chemotherapy vs chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase III KEYNOTE-590 study
    K Kato, J Sun, MA Shah
  • Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the checkmate 648 study
    I Chau, Y Doki, JA Ajani
  • Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer
    RJ Kelly, JA Ajani, J Kuzdzal
  • First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
    YY Janjigian, K Shitara, M Moehler
  • First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): expanded efficacy and safety data from CheckMate 649
    MH Moehler, K Shitara, M Garrido
  • First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
    YY Janjigian, SB Maron, WK Chatila
  • Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: a multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC)
    SY Rha, C-K Lee, H Kim
  • Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study
    YY Janjigian, A Kawazoe, PE Yanez
  • Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
    RS Finn, S Qin, M Ikeda
  • Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma
    RS Finn, M Ikeda, AX Zhu
  • Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): phase 3 LEAP-002 study
    JM Llovet, M Kudo, A-L Cheng
  • Pembrolizumab in microsatellite-instability—high advanced colorectal cancer
    T André, K-K Shiu, TW Kim
  • Final overall survival for the phase III KN177 study: pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
    T Andre, K-K Shiu, TW Kim
  • Durable clinical benefit with nivolumab plus Ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer
    MJ Overman, S Lonardi, KYM Wong
  • LEAP-005: a phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—results from the colorectal cancer cohort
    C Gomez-Roca, E Yanez, S-A Im
  • Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy
    EC Smyth, V Gambardella, A Cervantes